The use of imaging as biomarkers in drug development: Regulatory issues worldwide

Journal of Clinical Pharmacology

Volumn 41, Issue 7 SUPPL., 2001, Pages

  Katz, R ^a   Wagner, H N ^a   Fauntleroy, M ^a   Kuwert, T ^a   Frank, R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG;

ALZHEIMER DISEASE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG METABOLISM; EUROPE; MEDICAL DECISION MAKING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; VALIDATION PROCESS; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LEGAL ASPECT; PHARMACOLOGY;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; PHARMACOLOGY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035406036     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127001773744288     Document Type: Conference Paper

References (0)